VS-186B

VS-186B is an experimental small-molecule histone deacetylase (HDAC) inhibitor initially developed at the University of Texas at El Paso, being investigated in preclinical studies as an anticancer agent. In comparative in vitro work against a panel of HDAC inhibitors, VS-186B showed the greatest potency and the highest Selective Cytotoxic Index, indicating preferential cytotoxicity toward cancer cells over normal cells and supporting its potential as a safer, more effective epigenetic therapy candidate.[1][3] By inhibiting HDAC enzymes, VS-186B is designed to alter chromatin structure and gene expression to promote cancer cell apoptosis and growth arrest, and it remains in the preclinical research stage with no active clinical trials or commercial development disclosed.[1][3]